Spots Global Cancer Trial Database for Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)
Official Title: A Phase IIa, Single-arm, Open-label Study of MOR00208, a Humanized Fc-Engineered Anti-CD19 Antibody, in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
Study ID: NCT01685021
Conditions
Interventions
Study Description
Brief Summary: This is an open-label, multicentre study to characterize the safety and preliminary efficacy of the human anti CD19 antibody MOR00208 in adult subjects with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)
Detailed Description:
Eligibility
Minimum Age: 16 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Ohio State University Medical Center, Columbus, Ohio, United States
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Elias Jabbour, MD
Affiliation: MDA
Role: PRINCIPAL_INVESTIGATOR
Name: Rebecca Klisovic, MD
Affiliation: Ohio State University
Role: PRINCIPAL_INVESTIGATOR
Name: Wing H. Leung, M.D., PhD
Affiliation: St. Jude Children's Research Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
